Christopher Phelan1, Vivek Alaigh1, Gil Fortunato2, Ilene Staff2, Lauren Sansing3. 1. University of Connecticut School of Medicine, Farmington. 2. Research Program, Hartford Hospital, Hartford. 3. University of Connecticut School of Medicine, Farmington; Department of Neurology, Hartford Hospital, University of Connecticut Health Center, Farmington, CT. Electronic address: lauren.sansing@yale.edu.
Abstract
BACKGROUND: Ischemic stroke accounts for 85%-90% of all strokes and currently has very limited therapeutic options. Recent studies of β-adrenergic antagonists suggest they may have neuroprotective effects that lead to improved functional outcomes in rodent models of ischemic stroke; however, there are limited data in patients. We aimed to determine whether there was an improvement in mortality rates among patients who were taking β-blockers during the acute phase of their ischemic stroke. METHODS: A retrospective analysis of a prospectively collected database of ischemic stroke patients was performed. Patients who were on β-adrenergic antagonists both at home and during the first 3 days of hospitalization were compared with patients who were not on β-adrenergic antagonists to determine the association with patient mortality rates. RESULTS: The study included a patient population of 2804 patients. In univariate analysis, use of β-adrenergic antagonists was associated with older age, atrial fibrillation, hypertension, and more-severe initial stroke presentation. Despite this, multivariable analysis revealed a reduction in in-hospital mortality among patients who were treated with β-adrenergic antagonists (odds ratio, .657; 95% confidence interval, .655-.658). CONCLUSIONS: The continuation of home β-adrenergic antagonist medication during the first 3 days of hospitalization after an ischemic stroke is associated with a decrease in patient mortality. This supports the work done in rodent models suggesting neuroprotective effects of β-blockers after ischemic stroke.
BACKGROUND:Ischemic stroke accounts for 85%-90% of all strokes and currently has very limited therapeutic options. Recent studies of β-adrenergic antagonists suggest they may have neuroprotective effects that lead to improved functional outcomes in rodent models of ischemic stroke; however, there are limited data in patients. We aimed to determine whether there was an improvement in mortality rates among patients who were taking β-blockers during the acute phase of their ischemic stroke. METHODS: A retrospective analysis of a prospectively collected database of ischemic strokepatients was performed. Patients who were on β-adrenergic antagonists both at home and during the first 3 days of hospitalization were compared with patients who were not on β-adrenergic antagonists to determine the association with patient mortality rates. RESULTS: The study included a patient population of 2804 patients. In univariate analysis, use of β-adrenergic antagonists was associated with older age, atrial fibrillation, hypertension, and more-severe initial stroke presentation. Despite this, multivariable analysis revealed a reduction in in-hospital mortality among patients who were treated with β-adrenergic antagonists (odds ratio, .657; 95% confidence interval, .655-.658). CONCLUSIONS: The continuation of home β-adrenergic antagonist medication during the first 3 days of hospitalization after an ischemic stroke is associated with a decrease in patient mortality. This supports the work done in rodent models suggesting neuroprotective effects of β-blockers after ischemic stroke.
Authors: Craig T Ajmo; Lisa A Collier; Christopher C Leonardo; Aaron A Hall; Suzanne M Green; Tracy A Womble; Javier Cuevas; Alison E Willing; Keith R Pennypacker Journal: Exp Neurol Date: 2009-04-14 Impact factor: 5.330
Authors: Ilko L Maier; Johannes C Becker; Johanna Rosemarie Leyhe; Marlena Schnieder; Daniel Behme; Marios-Nikos Psychogios; Jan Liman Journal: PLoS One Date: 2018-04-25 Impact factor: 3.240